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Abstract
Background: The purpose of this study was to examine whether short-term ingestion of a powdered tart cherry
supplement prior to and following intense resistance-exercise attenuates muscle soreness and recovery strength
loss, while reducing markers of muscle damage, inflammation, and oxidative stress.
Methods: Twenty-three healthy, resistance-trained men (20.9 ± 2.6 yr, 14.2 ± 5.4 % body fat, 63.9 ± 8.6 kg FFM) were
matched based on relative maximal back squat strength, age, body weight, and fat free mass. Subjects were randomly
assigned to ingest, in a double blind manner, capsules containing a placebo (P, n = 12) or powdered tart cherries
[CherryPURE®] (TC, n = 11). Participants supplemented one time daily (480 mg/d) for 10-d including day of exercise up
to 48-h post-exercise. Subjects performed ten sets of ten repetitions at 70 % of a 1-RM back squat exercise. Fasting
blood samples, isokinetic MVCs, and quadriceps muscle soreness ratings were taken pre-lift, 60-min, 24-h, and 48-h
post-lift and analyzed by MANOVA with repeated measures.
Results: Muscle soreness perception in the vastus medialis (¼) (p = 0.10) and the vastus lateralis (¼) (p = 0.024) was
lower in TC over time compared to P. Compared to pre-lift, TC vastus medialis (¼) soreness was significantly attenuated
up to 48-h post-lift with vastus lateralis (¼) soreness significantly lower at 24-h post-lift compared to P. TC changes in
serum creatinine (p = 0.03, delta p = 0.024) and total protein (p = 0.018, delta p = 0.006) were lower over time and smaller
from pre-lift levels over time compared to P Significant TC group reductions from pre-lift levels were found for AST and
creatinine 48-h post-lift, bilirubin and ALT 60-min and 48-h post-lift. No significant supplementation effects were
observed for serum inflammatory or anti-inflammatory markers. None of the free radical production, lipid peroxidation,
or antioxidant capacity markers (NT, TBARS, TAS, SOD) demonstrated significant changes with supplementation. Changes
in TC whole blood lymphocyte counts (p = 0.013) from pre-lift were greater compared to P, but TC lymphocyte counts
returned to pre-lift values quicker than P.
Conclusion: Short-term supplementation of Montmorency powdered tart cherries surrounding a single bout of
resistance exercise, appears to be an effective dietary supplement to attenuate muscle soreness, strength decrement
during recovery, and markers of muscle catabolism in resistance trained individuals.
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Background
A large volume, high intensity strength training workout
activates a load-induced stress response characterized by
structural muscle damage, oxidative stress, and inflam-
mation that facilitates the release of intramuscular pro-
teins into systemic circulation that are usually associated
with cardiovascular dysfunction, invasive surgery, and
disease [1–4]. The repetitive nature of muscle contrac-
tions during bouts of high intensity exercise will induce
muscular injury as a result of ultrastructural disruptions
[3, 5–7] that ultimately lead to a muscular repair se-
quence of events: degeneration, inflammation, regener-
ation, and fibrosis [3, 8]. Muscle soreness following
exercise is not the direct result of inflammation, but ra-
ther a product of high nociceptor and mechanoreceptor
sensitivity to the potent chemicals and by-products re-
leased during muscular degeneration [5, 9, 10]. Millions
of people, including athletes, use non-steroidal anti-
inflammatory drugs (NSAIDs) to help reduce pain and
inflammation [3, 5]. NSAID use mitigates the inflammatory
response via non-specific inhibition of the cyclooxygenase
(COX-1 and COX-2) enzymes that regulate production of
inflammatory-stimulating prostaglandins [3, 5, 11]. How-
ever, NSAIDs remain controversial as some research has
demonstrated that muscle protein synthesis and the func-
tion of satellite cells in skeletal muscle hypertrophy are
compromised when COX enzymes are inhibited [12–16],
while other studies have found no NSAID effect on post-
exercise anabolic processes within muscle [17–19].
Due to the debate surrounding the use of NSAIDs in sport
and exercise applications, performance nutrition research
has more recently shifted focus toward phytochemical-
containing fruits and other functional foods that seem to
provide a beneficial anti-inflammatory and antioxidant ef-
fect [20, 21]. A wide variety of antioxidant and polyphenol-
containing functional foods such as purple sweet potatoes
[22–24], beet root juice [25–27], cranberries [28, 29], and
blueberries [30, 31] have verified health, performance-
enhancing, and exercise recovery benefits. However, com-
pared to other functional foods, the high anthocyanin
content of both tart (e.g. Montmorency cherries) and sweet
(e.g. Bing cherries) [21, 32–34] have proven beneficial
in health [35–38], inflammatory-related disease states
(e.g. cardiovascular disease, diabetes, osteoarthritis,
gout) [35, 36, 38–40], and sleep quality [41, 42]. Clin-
ical supplementation success with cherries, particularly
tart cherry whole fruit, concentrates and cultivar juice
blends, spurred an increase in exercise-based research
to prove beneficial effects in mitigating muscle damage,
oxidative stress, inflammation, and muscle pain with an
impetus to increase performance [21, 43, 44].
We are aware of only two studies that have evaluated
the effects of tart cherry supplementation on responses to
resistance-based exercise. The first study examined 8-d of
tart cherry cultivar-blended juice supplementation on ex-
ercise-induced muscle pain surrounding a bout of 40 max-
imal eccentric elbow flexion contractions (2 sets × 20
repetitions) [20]. As a result of tart cherry supplementation,
strength losses and exercise-induced muscle pain were at-
tenuated compared to a placebo over 4-d of maximal
eccentric elbow flexion exercise [20]. No hematological
analysis was performed to decipher potential physiological
effects of supplementation. A second study examined the
effects of 10-d tart cherry concentrate supplementation on
physiological markers of muscle damage, oxidative stress,
inflammation, muscle function, and muscle pain surround-
ing an intensive single-leg 100 repetition knee extensor
training session (10 sets × 10 repetitions) [4]. Similar to the
first study, functional recovery of isometric muscle strength
was greater as a result of tart cherry supplementation com-
pared to placebo [4]. Hematological analysis demonstrated
reduced oxidative stress following the leg extension proto-
col that supported the beneficial functional recovery results
in the tart cherry trial [4]. Interestingly, a recent endurance-
based study with blended Montmorency tart cherry juice
supplementation evaluating stress, inflammation, and upper
respiratory symptoms following a marathon run demon-
strated an attenuation of post-race incidence and severity of
upper respiratory tract symptoms and inflammation (serum
CRP) [45]. The primary aim of the current study was to
determine if this powdered supplement derived from tart
cherry skins would promote similar attenuation of muscle
soreness, strength losses, and oxidative damage as the tart
cherry cultivar-blended juice and juice concentrate supple-
mented in the two previous resistance exercise studies. The
secondary objective of this study was to determine whether
short-term (10-d) ingestion of the powdered tart cherry for-
mulation prior to and following a lower body strength exer-
cise protocol of high volume and intensity will effectively
reduce markers of muscle damage, muscle soreness, inflam-
mation, oxidative stress, and attenuate strength losses dur-
ing subsequent exercise performance.
Methods
Subjects
Twenty-three healthy, resistance-trained males (20.9 ±
2.6 yr, 81.7 ± 10.3 kg 14.2 ± 5.4 % body fat, 63.9 ± 8.6 kg
FFM) participated as subjects in this study. Subjects
were recruited through paper and electronically distrib-
uted study advertisements at Texas A&M University.
Entrance criteria required subjects to have been involved
in a progressive resistance training program that in-
cluded regular squat exercise for at least 6 months prior
to study recruitment and be able to perform a standard
barbell back squat in a Smith machine rack of at least
1.5 times their body weight. Proper performance of bar-
bell back squat technique was determined by a National
Strength and Conditioning Association (NSCA) Certified
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Strength and Conditioning Coach (CSCS) during base-
line testing. Figure 1 demonstrates the breakdown of the
subject population as it pertains to the study progres-
sion. Discontinuation of any subject participation was
not related to any aspect of the supplementation or test-
ing protocol.
All subjects signed informed consent documents and
the study was approved by the Texas A&M University
Institutional Review Board prior to any data collection.
Subjects were not allowed to participate in this study if
they reported any of the following: 1) any metabolic disor-
ders or taking any thyroid, hyperlipidemic, hypoglycemic,
anti-hypertensive, anti-inflammatory (e.g. NSAIDs), and/
or androgenic medications; 2) history of hypertension,
hepatorenal, musculoskeletal, autoimmune, and/or neuro-
logical disease(s); 3) allergy to cherries or any cherry com-
ponents (e.g. polyphenols, anthocyanins, anthocyanidins).
Experimental design
Figure 2 shows the experimental design used in this study.
The study was conducted in a randomized, double-blind,
and placebo-controlled manner. All subjects eligible to par-
ticipate in the study completed a morning familiarization
(FAM) session where they were provided detailed informa-
tion regarding the study design, testing procedures, and
supplementation protocols. Informed consent, medical
history, and endurance training history questionnaires were
also completed during the FAM session. A research nurse
reviewed medical history documents and performed a
physical exam on each subject to ensure safety and partici-
pation eligibility. A fasting blood sample was taken at the
end of the FAM session if the subject met entrance criteria.
Subjects were asked to not change their dietary habits in
any way throughout the study (upon start of supplementa-
tion). This was monitored by subject documentation of
dietary intake for 4-d (3 weekdays and 1 weekend day) of
the first seven supplementation days prior to the resistance
exercise challenge. Approximately 10-d prior to the resist-
ance exercise intervention, eligible subjects returned to the
lab for a morning baseline testing session to determine
body weight, height, and body composition. The subjects
then were familiarized with the maximal voluntary con-
traction (MVC) protocol using their dominant leg on an
isokinetic knee extension dynamometer followed by a 5-
min recovery before determination of their barbell back
squat 1-repetition maximum (1-RM) in a Smith ma-
chine rack. Following baseline measurements, subjects
were matched based on relative maximal back squat
strength, fat free mass, body weight, and age accompanied
by a random separation into two groups: 1) a placebo
group or 2) a powdered tart cherry group.
Subjects were instructed to begin supplementation 7-d
prior to the resistance exercise challenge (Day 0). Sub-
jects were asked to fast overnight for 10-h to account
Fig. 1 Consort diagram breakdown of the subject population as it pertains to the various stages of study progression
Levers et al. Journal of the International Society of Sports Nutrition  (2015) 12:41 Page 3 of 23
for diurnal variation as well as refrain from exercise and
consumption of NSAIDs for 48-h prior to all testing
days. Due to the large variety of NSAIDs commonly
available with half-life data ranging from approximately
1.6 to 30-h [46], the 48-h restriction was implemented
to help reduce any potential concurrent effects. Exercise
logs were not implemented to track subject activity pat-
terns over the study protocol. On the day of the resist-
ance exercise challenge, subjects reported to the lab
where body weight, resting heart rate, and resting blood
pressure were measured. Subjects then donated a fasting
venous blood sample (approximately 20 ml) using stand-
ard clinical procedures and rated perceptions of muscle
soreness to a standardized application of pressure on
their dominant thigh at three designed locations using a
graphic pain rating scale (GPRS). The subjects then
completed the MVC protocol using their dominant leg
on an isokinetic knee extension dynamometer followed
by a 5-min recovery before the barbell back squat proto-
col utilizing a Smith machine rack was completed with a
Tendo power and speed analyzer attached to the bar.
Fasting (except 60-min post-lift) blood samples, GPRS
ratings of quadriceps muscle soreness, and the isokinetic
leg extension MVC protocol were completed at 60-min,
24-h and 48-h of post-lift recovery. The last day of sup-
plementation correlated with 48-h post-lift recovery.
Exercise protocol
Isokinetic knee extension maximal voluntary contractions
At baseline, before the squat exercise, 60-min after the
squat exercise, 24-h and 48-h post-lift exercise, subjects
performed an isokinetic knee extension MVC test using
their dominant leg on a Kin-Kom 125AP Isokinetic
Dynamometer (Chattanooga-DJO Global Inc., Vista, CA,
USA). During the baseline familiarization of the isokin-
etic leg extension MVC protocol, standard procedures
were used to determine and record proper subject posi-
tioning on the Kin-Kom to ensure accurate repeatability
of the testing protocol across all five sessions. The sub-
ject warmed-up on the isokinetic dynamometer by per-
forming three-sets of five repetitions of dominant knee
extension/flexion at 50 % of their MVC (determined
during the FAM) with 1-min recovery between sets.
After the 1-min recovery following the third warm-up
set, the subject performed 3 MVCs in succession with
no rest between contractions. Subjects were allotted a 5-
min recovery between the isokinetic MVC and barbell
back squat protocols. Test to test variability of perform-
ing this test yielded average CV values of ±8.47 % with a
test retest correlation of r = 0.88.
Barbell back squat 1-repetition maximum determination
At baseline, following the 5-min recovery after the isokin-
etic MVCs, subjects performed three-sets of five repeti-
tions of a barbell back squat on a Smith machine rack
(Life Fitness, Schiller Park, IL, USA, model SSM) at 50 %
of their anticipated 1-RM with 2-min recovery between
sets. Following the warm-up protocol, the barbell back squat
1-RM was determined on the Smith machine rack using a
standard 1-RM protocol defined by the NSCA with 2-min
recovery periods between 1- repetition sets of increasing
weight. All 1-RM determinations were made within 3–5 sets
beyond the warm-up. In order to successfully complete each
set, the subject was required to reach thigh parallel depth as
determined by a NSCA Certified Strength and Conditioning
Coach (CSCS) providing a verbal “up” cue during spotting.
Fig. 2 Experimental study design. DEXA = dual-energy X-Ray absorptiometer, MVC =maximal voluntary contraction, 1-RM = 1-repetition maximum,
NSAID = non-steroidal anti-inflammatory drugs, GPRS = graphic pain rating scale, 7-d = 7-day, 48-h = 48-hour
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Barbell back squat exercise protocol
On the day of the resistance exercise challenge, following
the 5-min recovery after the isokinetic MVCs, subjects
performed one warm-up set of ten repetitions of the bar-
bell back squat at 50 % 1-RM (determined during base-
line). After 3-min recovery, the subjects performed ten
sets of ten repetitions of a barbell back squat at 70 % 1-
RM with 3-min recovery between sets. If necessary, the
barbell back squat resistance was adjusted such that each
subject completed the 100 repetition (10 sets × 10 repeti-
tions) volume to thigh parallel depth, keeping the training
volume consistent across the study population. This
protocol is closely replicated after the repeated leg ex-
tension exercise implemented previously by Bowtell et
al. [4]. A Tendo Power and Speed Analyzer (TENDO
Sports Machines, Trencin, Slovak Republic, model
PSA310) was attached to the bar during all 100 repeti-
tions completed during the squat protocol to determine
peak power, average force, and total work for each repe-
tition. Following the squat protocol, subjects were only
permitted to stretch with limited ambulation until the
60-min post-lift testing protocol was completed.
Supplementation protocol
Subjects were assigned in a double-blinded and random-
ized manner to ingest either a rice flour placebo (P, n = 12)
or powdered tart cherry (TC, n = 11). Subjects were
matched into one of the two groups according to relative
maximal back squat strength, fat free mass, body weight,
and age. Subjects were instructed to ingest 480 mg of the
supplements with breakfast at 0800 7-d prior to, the day
of, and 2-d following the resistance exercise challenge for
a total supplementation timeline of 10-d. The tart cherry
supplements contained 480 mg of freeze dried Montmo-
rency tart cherry skin powder derived from tart cherry
skins obtained after juicing (CherryPURE™ Freeze Dried
Tart Cherry Powder, Shoreline Fruit, LLC, Transverse City,
MI, USA). Prior analytical testing conducted in 2012 by
Atlas Bioscience (Tuscon, AZ, USA) demonstrated that
290 mg of CherryPURE™ provides approximately 600 mg
of phenolic compounds and 40 mg of anthocyanins, which
is equivalent to consuming 10.5 fluid ounces of tart cherry
juice. The supplements were prepared for distribution by
Shoreline Fruit, LLC and sent to Advanced Laboratories
(Salt Lake City, UT, USA) to quantify total phenolic com-
pound and anthocyanin content of the powdered tart
cherry supplements. Supplements were prepared in stan-
dardized color capsules and packaged in generic bottles by
Shoreline Fruit, LLC for double blind administration.
Procedures
Dietary inventories
Within the first 7-d of supplementation, subjects were
instructed to record all food and fluid intake over a 4-d
period (3 weekdays, 1 weekend day), which was reflect-
ive of their normal dietary intake. Dietary inventories
were then reviewed by a registered dietician and ana-
lyzed for average energy, macronutrient, and dietary
antioxidant intake using ESHA Food Processor (Version
8.6) Nutritional Analysis software (ESHA Research Inc.,
Salem, OR, USA).
Anthropometrics and body composition
At the beginning of every testing session, subjects had
their height and body mass measured according to stand-
ard procedures using a Healthometer Professional 500KL
(Pelstar LLC, Alsip, IL, USA) self-calibrating digital scale
with an accuracy of ± 0.02 kg. Whole body bone density
and body composition measures (excluding cranium) were
determined with a Hologic Discovery W Dual-Energy X-
ray Absorptiometer (DEXA; Hologic Inc., Waltham, MA,
USA) equipped with APEX Software (APEX Corporation
Software, Pittsburg, PA, USA) by using procedures previ-
ously described [47, 48]. Mean test-retest reliability studies
performed on male athletes in our lab with this DEXA
machine have revealed mean coefficients of variation for
total bone mineral content and total fat free/soft tissue
mass of 0.31–0.45 % with a mean intraclass correlation of
0.985 [49]. On the day of each test, the equipment was
calibrated following the manufacturer’s guidelines.
Muscle soreness perception measurement
Pressure application to the three specified areas of the
quadriceps muscle group on the subject’s dominant leg
was standardized to 50 N of pressure using a handheld
Commander Algometer (JTECH Medical, Salt Lake City,
UT, USA). Force was applied to each site of muscle con-
tact with a cylindrical metal probe through a 1 cm diam-
eter head. The standard amount of pressure was applied
to the vastus lateralis (VL) at both 25 and 50 % of the
distance between the superior border of the patella and
the greater trochanter of the femur at the hip and to the
vastus medalis (VM) at 25 % of the distance between the
aforementioned landmarks. These three specific loca-
tions were measured and marked with a permanent
marker on each subject during the initial muscle sore-
ness perception measurement before the resistance exer-
cise challenge. The participants were asked to maintain
these three marked locations between testing sessions to
avoid error with secondary measurement. The subject
was seated in a reclined supine position and given the
GPRS sheet to evaluate the perception of muscle sore-
ness at each of the three quadriceps locations. The order
of pressure application was standardized across all ses-
sions and participants: 25 % VM, 25 % VL, and 50 % VL.
The 50 N of pressure was applied to a relaxed quadriceps
at each of the three locations using the algometer for a
period of 3-sec to give the subject enough time to record
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their soreness evaluation on the GPRS. Perceptions of
muscle soreness were recorded by measuring the dis-
tance (centimeters) of the participant mark on the GPRS
from 0 cm (no pain). Test-to-test reliability for this
protocol revealed a mean intraclass correlation of 0.90.
Blood collection
Subjects were required to fast (except 60-min post-lift)
for 10-h prior to donating approximately four teaspoons
(20 mL) of venous blood from an antecubital vein using
standard phlebotomy procedures at each of the testing
sessions. Blood analyzed for markers of muscle damage,
oxidative stress, inflammation, and clinical chemistry
panels were collected in two 7.5 mL BD Vacutainer®
serum separation tubes (Becton, Dickinson and Com-
pany, Franklin Lakes, NJ, USA), left at room temperature
for 15-min, and then centrifuged at 3500 rpm for 10-
min using a standard, refrigerated (4 °C) bench top
Thermo Scientific Heraeus MegaFuge 40R Centrifuge
(Thermo Electron North America LLC, West Palm Beach,
FL, USA). Serum supernatant was removed and stored
at −80 °C in polypropylene microcentrifuge tubes for
later analysis. Blood was also collected in a single 3.5 mL
BD Vacutainer® lavender top tube containing K2 EDTA
(Becton, Dickinson and Company, Franklin Lakes, NJ,
USA), left at room temperature for 15-min, and refriger-
ated for approximately 3–4 h before subsequent
complete blood count analysis.
Clinical chemistry analysis
Whole blood samples were analyzed for complete blood
count with platelet differentials (hemoglobin, hematocrit,
red blood cell counts (RBC), white blood cell counts
(WBC), lymphocytes, granulocytes (GRAN), and mid-
range absolute count (MID)) using an Abbott Cell Dyn
1800 (Abbott Laboratories, Abbott Park, IL, USA) auto-
mated hematology analyzer. Internal quality control for
the Abbott Cell Dyn 1800 was performed using three
levels of control fluids purchased from the manufacturer
to calibrate acceptable standard deviation (SD) and coef-
ficients of variation (CV) values for all aforementioned
whole blood cell counts. Serum samples were analyzed
using a Cobas c111 (Roche Diagnostics GmbH, Indian-
apolis, IN, USA) automated clinical chemistry analyzer
that was calibrated and optimized according to manufac-
turer guidelines. This analyzer has been known to be
highly valid and reliable in previously published reports
[50]. Each serum sample was assayed for a standard par-
tial metabolic panel [(aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and total bilirubin)] and
clinical markers of protein and fatty acid metabolism
[(uric acid, creatinine, blood urea nitrogen (BUN), total
protein, and creatine kinase (CK)]. The internal quality
control for the Cobas c111 was performed using two
levels of control fluids purchased from the manufacturer
to calibrate acceptable SD and CV values for all afore-
mentioned assays. Samples were re-run if the observed
values were outside control values and/or clinical norms
according to standard procedures.
Markers of anabolic/catabolic hormone status
Serum samples were assayed using standard commer-
cially available enzyme-linked immunosorbent assay kits
(ELISAs) for cortisol and testosterone (ALPCO Diagnos-
tics, Salem, NH, USA) hormone analysis. Serum concen-
trations were determined calorimetrically using a BioTek
ELX-808 Ultramicroplate reader (BioTek Instruments
Inc., Winooski, VT, USA) at an optical density of 450 nm
against a known standard curve using manufacturer rec-
ommended procedures. Samples were run in duplicate
according to standard procedures to ensure validity of
measurement. Test to test variability of performing these
assays yielded average CV values for the aforementioned
markers of: CORT (±6.85 %), and TEST (±4.47 %) with
a test retest correlation for the same markers of: CORT
(r = 0.92), TEST (r = 0.98).
Markers of oxidative stress
Serum samples were assayed using standard commer-
cially available ELISA kits for Superoxide Dismutase
(SOD Activity Assay kit), Total Antioxidant Status (TAS,
Antioxidant Assay kit), Thiobarbituric Acid Reactive Sub-
stance (TBARS, Malondialdehyde-MDA, TCA method
kit) (Cayman Chemical Company, Ann Arbor, MI, USA),
and Nitrotyrosine (ALPCO Diagnostics, Salem, NH, USA).
Serum concentrations for SOD and Nitrotyrosine were
determined calorimetrically using the previously stated
instrumentation at the same optical density (450 nm)
against a known standard curve using standard proce-
dures. Serum concentrations for TAS were also determined
calorimetrically using the aforementioned instrumentation
at an optical density of 405 nm against a known standard
curve using standard procedures. Lastly, serum concentra-
tions for TBARS were also determined fluorometrically
using a SpectraMax Gemini multimode plate reader
(Molecular Devices LLC, Sunnyvale, CA, USA) at an ex-
citation wavelength of 530 nm and an emission wave-
length of 550 nm against a known standard curve using
standard procedures. Samples were run in duplicate ac-
cording to standard procedures to ensure validity of
measurement. Test to test variability of performing
these assays yielded average CV values for the afore-
mentioned markers of: SOD (±8.35 %), TAS (±14.24 %),
TBARS (±8.30 %), and NT (±10.03 %) with a test retest
correlation for the same markers of: SOD (r = 0.83),
TAS (r = 0.85), TBARS (r = 0.94), and NT (r = 0.99).
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Cytokine/Chemokine markers of inflammation
Serum markers of inflammation [(interleukin-1β (IL-1β),
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13,
tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ),
and granulocyte-macrophage colony-stimulating factor
(GM-CSF)] were measured by using a commercially
available Milliplex MAP 13-Plex Human High Sensitivity
T-Cell Magnetic Bead Panel kit (EMD Millipore Corpor-
ation, St. Charles, MO, USA) that was optimized for hu-
man serum samples. A minimum of 100 positive beads
for each cytokine/chemokine was acquired with a Lumi-
nex MagPix instrument (Luminex Corporation, Austin,
TX, USA). This instrument has been proven to be highly
valid and reliable in previously published reports across
many disciplines [51–54]. Manufacturer supplied con-
trols were used to monitor the coefficients of variation.
Samples were run in duplicate according to standard
procedures to ensure validity of measurement. Test to
test variability of performing these assays yielded average
CV values for the aforementioned markers of: IL-1β
(±4.37 %), IL-2 (±5.52 %), IL-4 (±4.59 %), IL-5 (±4.30 %),
IL-6 (±4.26 %), IL-7 (±5.05 %), IL-8 (±4.55 %), IL-10
(±5.05 %), IL-12p70 (±4.92 %), IL-13 (±4.99 %),TNF-α
(±6.05 %), IFN-γ (±4.42 %), and GM-CSF (±5.22 %) with
a test retest correlation for the same markers of: IL-1β
(r = 0.98), IL-2 (r = 0.99), IL-4 (r = 0.99), IL-5 (r = 0.99), IL-6
(r = 0.99), IL-7 (r = 0.99), IL-8 (r = 0.99), IL-10 (r = 1.00),
IL-12p70 (r = 1.00), IL-13 (r = 0.99), TNF-α (r = 0.95),
IFN-γ (r = 1.00), and GM-CSF (r = 1.00).
Statistical analysis
Individual group and time data are presented throughout
the text and in all tables as means (± SD), while group
effects are presented as means (± SEM). All related vari-
ables were grouped and analyzed using repeated mea-
sures MANOVA in IBM SPSS Statistics Software version
22.0 for Windows (IBM Corporation, Armonk, NY, USA)
to assess values observed and changes from pre-lift
levels in response to the supplement administered. Post-
hoc LSD pairwise comparisons were used to analyze any
significance among groups where needed with Cohen’s d
calculations employed to determine effect magnitude.
Data was considered statistically significant when the
probability of error was less than 0.05 and considered to
be trending when the probability of error was less than
0.10. Statistical trends (p < 0.05 to p < 0.10) were noted
as is common practice in studies with relatively small
sample size [55].
Results
Subject baseline characteristics
A total of 23 healthy, resistance-trained men completed
the protocol for this study. Participants were 20.9 ±
2.6 years, 81.7 ± 10.3 kg, 14.2 ± 5.4 % body fat, and 63.9 ±
8.6 kg fat free mass. Participant demographic data are pre-
sented in Table 1. One-way ANOVA revealed no significant
differences (p > 0.05) in baseline demographic markers. No
significant differences in back squat 1-RM (p = 0.70) and
relative squat strength ratio (p = 0.85) were reported across
groups, hence the groups were generally well matched.
One-way ANOVA analysis also demonstrated no differ-
ences in total work performed (p = 0.79) across groups, in-
dicating that similar work was performed during the
exercise intervention and differences can likely be attrib-
uted to the nutritional intervention.
Nutritional intake and compliance
Nutritional intake was monitored over a 4-d period
within the first 7-d of supplementation. Relevant nutri-
tional components analyzed are listed in Table 2. No sta-
tistically significant interactions were observed across
groups with respect to dietary intake.
Muscle soreness perception assessment
Table 3 presents perceptions of muscle soreness across
the resistance exercise protocol. The overall MANOVA
analysis revealed a significant overall Wilks’ Lambda
time (p < 0.001) interaction and a non-significant overall
group x time effect (p = 0.20). Perception of muscle sore-
ness in all three muscle testing locations irrespective of
group significantly increased over time, peaking 48-h
post-lift, indicating the onset of muscle soreness as a
result of the lifting protocol. A significant difference
between groups over time was found in vastus lateralis
(¼) soreness perception (p = 0.024) where ratings in-
creased by 55–170 % from pre-lift values in P, but only
35–104 % in TC over the recovery. Post-hoc analysis in-
dicated a significantly attenuated increase in muscle
soreness perception 24-h post-lift for TC supplementing
subjects compared to P (see Fig. 3). Effects of supple-
mentation tended to be different in the perception of
vastus medialis (¼) soreness (p = 0.10) with significantly
lower muscle soreness in TC versus P up to 48-h post-
lift (see Fig. 3). Soreness perception ratings in the vastus
medialis (¼) increased by 28–83 % from pre-lift values
in P, but ranged from a 6 % decrease to only a 58 %
increase in TC over the recovery.
Isokinetic maximal voluntary contraction performance
assessment
Table 4 reports the total work performed during the 3-
repetition isokinetic flexion/extension MVC test. The
overall MANOVA analysis revealed both a non-significant
Wilks’ Lambda time interaction (p = 0.96) and a non-
significant group x time effect (p = 0.75). The 3-repetition
work summation univariate measures for extension (p <
0.001), flexion (p = 0.022), and total (p < 0.001) demon-
strated significant changes over time, with the lowest work
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attained 60-min post-lift in all three measures. No aspect
of the isokinetic strength recovery work performed dem-
onstrated a significant group effect over time. While
changes from pre-lift were not statistically significant
between groups across time, the drop in 3-repetition sum-
mation of flexion (p = 0.21; d = 0.45), extension (p = 0.23;
d = 0.45), and total work (p = 0.15; d = 0.55) performed 60-
min post-lift may have been attenuated in TC compared
Table 1 Demographics by Study Group
Variable Group Mean Group (SEM) p-value
N P 12 n/a n/a
TC 11 n/a
Total 23 n/a
Age P 20.58±1.78 0.51 0.593
TC 21.18±3.34 1.01
Total 20.87±2.60 0.54
Height (cm) P 177±5.28 1.52 0.651
TC 178±10.71 3.23
Total 177±8.17 1.70
Weight (kg) P 82.62±7.39 2.13 0.659
TC 80.64±13.16 3.97
Total 81.67±10.35 2.16
Baseline HR (bpm) P 61.17±10.40 3.00 0.195
TC 66.09±6.67 2.01
Total 63.52±8.98 1.87
BMD (g/cm2) P 1.16±0.10 0.03 0.389
TC 1.12±0.14 0.04
Total 1.14±0.12 0.02
LM (kg) P 61.41±4.87 1.41 0.970
TC 61.55±11.16 3.36
Total 61.48±8.27 1.73
FFM (kg) P 63.83±5.06 1.46 0.981
TC 63.92±11.64 3.51
Total 63.87±8.62 1.80
FM (kg) P 11.81±5.44 1.57 0.595
TC 14.10±13.58 4.09
Total 12.90±10.00 2.08
Body Fat (%) P 15.31±6.27 1.81 0.338
TC 13.09±4.31 1.30
Total 14.25±5.42 1.13
Back Squat 1-RM (lbs) P 318±62 18.03 0.696
TC 306±82 24.72
Total 313±71 14.81
Relative Squat Strength Ratio P 1.75±0.27 0.08 0.855
TC 1.73±0.34 0.10
Total 1.74±0.30 0.06
Workout Total Work (kJ) P 0.68±0.14 0.04 0.798
TC 0.70±0.23 0.07
Total 0.69±0.18 0.04
Mean data expressed as means ± SD
HR heart rate, BMD bone mineral density, LM lean mass, FFM free-fat mass, FM fat mass, 1-RM 1-Repetition maximum
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to P based upon the moderate to large Cohen’s d effect
size calculations. Average recovery decreases in flexion,
extension, and total work performance from pre-lift values
were 5, 19, and 14 % respectively in P, but only 2, 16, and
10 % in TC.
Markers of mechanical damage and physiological stress
Table 5 presents the serum mechanical damage and
physiological stress markers tested in the standard clinical
safety panel. The overall MANOVA analysis revealed a
significant overall Wilks’ Lambda time (p < 0.001) effect,
Table 2 Dietary Analysis by Study Group
Variable Group Mean Group (SEM) p-value
Average Daily Caloric Consumption (kcal) P 2617±721 208 0.605
TC 2455±753 227
Total 2540±724 151
Dietary Protein (g) P 147.86±43.13 12.45 0.871
TC 153.06±100.39 30.27
Total 150.35±74.28 15.49
Dietary Carbohydrates (g) P 244.47±62.58 18.07 0.460
TC 223.52±70.90 21.38
Total 234.45±66.01 13.76
Dietary Fat (g) P 84.54±23.55 6.80 0.427
TC 95.23±38.55 11.62
Total 89.65±31.35 6.54
Dietary Beta-Carotene (mcg) P 2954±3436 992 0.651
TC 2111±5260 1586
Total 2551±4320 901
Dietary Vitamin C [Ascorbic Acid] (mg) P 80.79±65.99 19.05 0.199
TC 50.56±38.41 11.58
Total 66.33±55.55 11.58
Dietary Vitamin E [Alpha-Tocopherol] (mg) P 5.91±6.04 1.74 0.910
TC 6.24±7.44 2.24
Total 6.07±6.59 1.37
Mean data expressed as means ± SD
Table 3 Quadriceps Muscle Soreness Perception
Variable Group Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
Algo I (cm) P 4.34±2.52 5.53±3.15 7.78±2.93 7.94±2.92 6.40±0.76 G=0.139
TC 3.80±2.86 3.59±2.76 5.50±2.68 5.99±3.59 4.72±0.79 T<0.001* TL<0.001*
Time Mean 4.07±0.56 4.56±0.62 6.64±0.59Ψ◊ 6.96±0.68Ψ◊ G X T=0.236 G X Tq=0.172
Algo II (cm) P 2.44±1.60 3.76±2.24Ψ 6.60±2.99^Ψ◊ 6.20±3.64Ψ◊ 4.75±0.69 G=0.773
TC 2.98±2.70 4.03±2.93Ψ 4.76±3.03Ψ 6.07±3.67Ψ◊# 4.46±0.72 T<0.001* TL<0.001*
Time Mean 2.71±0.46 3.90±0.54Ψ 5.68±0.63Ψ◊ 6.14±0.76Ψ◊ G X T=0.187 G X Tq=0.024*
Algo III (cm) P 3.25±2.65 3.42±3.24 6.55±3.80 6.18±3.36 4.85±0.81 G=0.609
TC 2.68±2.67 3.76±3.18 4.89±3.87 5.64±3.74 4.24±0.85 T<0.001* TL<0.001*
Time Mean 2.96±0.55 3.59±0.67 5.72±0.80Ψ◊ 5.91±0.74Ψ◊ G X T=0.427 G X TL=0.690
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents the participant soreness perception
in the quadriceps muscle group at each test session during the 10 day intervention. MANOVA analysis revealed overall Wilks' Lambda time (p<0.001) and group x
time (p=0.199). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. Univariate ANOVA p-levels are listed first by the Greenhouse-
Geisser (GG) analysis and then by the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x time interaction with significance
indicated by the following super/subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD post hoc analysis is indicated by
the following superscripts: ^ represents p<0.05 difference between groups, Ψ represents p<0.05 difference from pre-lift, ◊ represents p<0.05 difference from 60-
min post, # represents p<0.05 difference from 24-hr post. Algo I = Algometer location #1: Vastus Medalis 1/4; Algo II = Algometer location #2: Vastus Lateralis 1/4;
Algo III = Algometer location #3: Vastus Lateralis 1/2; G = group p-level; T = time p-level; G x T = interaction; q = quadratic p-level; L = linear p-level
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Fig. 3 Perceptions of muscle soreness. Data expressed as means ± SE and significance indicated by the following super/subscripts: * indicates p < 0.05
p-level significance, § indicates p< 0.10 p-level significance. LSD post hoc analysis is indicated by the following superscripts: ^ represents p< 0.05 difference
between groups, Ψ represents p< 0.05 difference from pre-lift, ◊ represents p< 0.05 difference from 60-min post, # represents p< 0.05 difference from
24-h post
Table 4 Isokinetic Maximal Voluntary Contraction Knee Extension/Flexion Total Work Performance
Variable Group Baseline Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
IK Total Ext Work (N) P 1791±207 1682±235 1278±275 1408±296 1387±291 1509±90 G=0.870
TC 1757±378 1612±437 1298±422 1418±463 1352±383 1487±94 T<0.001* TL<0.001*
Time Mean 1774±295 1648±340† 1288±345†Ψ 1413±376†Ψ◊ 1370±331†Ψ G X T=0.792 G X Tq=0.662
IK Total Flex Work (N) P 971±126^ 962±141^ 913±174^ 925±153^ 910±113^† 936±58 G=0.181
TC 1073±252 1060±277 1064±225 1058±305 1010±289† 1053±61 T=0.087§ TL=0.022*
Time Mean 1020±199 1009±218 986±210 989±242 958±217†Ψ G X T=0.663 G X Tq=0.206
IK Total Work (N) P 2762±293 2644±354 2191±388 2333±407 2296±373 2445±141 G=0.646
TC 2829±611 2673±687 2363±603 2476±733 2362±644 2540±148 T<0.001* TL<0.001*
Time Mean 2794±462 2658±527† 2273±498†Ψ 2401±577†Ψ◊ 2328±509†Ψ G X T=0.692 G X Tq=0.470
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents the isokinetic MVC knee extension
and flexion performance each test session during the 10 day intervention. MANOVA analysis revealed overall Wilks' Lambda time (p<0.960) and group x time
(p=0.748). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. Univariate ANOVA p-levels are listed first by the Greenhouse-Geisser
(GG) analysis and then by the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x time interaction with significance
indicated by the following super/subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD post hoc analysis is indicated by
the following superscripts: ^ represents p<0.05 difference between groups, † represents p<0.05 difference from baseline value, Ψ represents p<0.05 difference
from pre-lift, ◊ represents p<0.05 difference from 60-min post, # represents p<0.05 difference from 24-hr post. Ext = extension; Flex = flexion; IK = isokinetic; MVC
= maximal voluntary contraction; G = group p-level; T = time p-level; G x T = interaction; q = quadratic p-level; L = linear p-level
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but no difference between groups over time (p = 0.50).
Univariate measures for uric acid (p < 0.001), total biliru-
bin (p = 0.026), creatinine (p = 0.003), and total protein
(p < 0.001) demonstrated significant changes over time,
peaking 60-min post-lift. CK (p = 0.025) and AST (p =
0.003) also significantly changed over time, peaking 24-h
post-lift. Significant group differences over time and group
by time changes from pre-lift were reported for creatinine
(p = 0.030, delta p = 0.024) and total protein (p = 0.018,
delta p = 0.006). Analyzing the change from pre-lift
levels, significant differences across groups for creatinine
(p = 0.007) and total protein (p = 0.004) were also evident.
Serum creatinine increased on average 2 % over pre-lift
values during the recovery in P, but actually decreased 7 %
below pre-lift in TC. Serum total protein increased 2–9 %
over pre-lift values during the recovery in P, but decreased
0–4 % below pre-lift in TC. Subsequent post-hoc analysis
indicated a significantly attenuated TC creatinine response
48-h post-lift and a TC total protein level that never dif-
fered from pre-lift measures 60-min and 48-h post-lift
compared to deviations in P (see Fig. 4). Increases in serum
CK levels tended to be lower in TC over time compared to
P (p = 0.10). Serum CK levels increased on average 135 %
over pre-lift values during the recovery in P, but increased
only 98 % in TC. No other significant differences between
groups over time or deviations from normal human clinical
ranges were observed for kidney/liver enzymes [e.g. AST
(p = 0.16), ALT (p = 0.27)] or markers of protein catab-
olism [bilirubin (p = 0.12), BUN:creatinine ratio (p =
0.39), uric acid (p = 0.15)]. However, further post-hoc
analyses revealed TC facilitated post-lift attenuations in
bilirubin, AST, and ALT 48-h post-lift compared to P
(see Figs. 4 and 5).
Anabolic/catabolic hormone response markers
Table 6 shows the serum anabolic and catabolic hormone
markers analyzed in response to exercise. The overall
MANOVA analyses revealed both non-significant overall
Wilks’ Lambda time (p = 0.29) and overall group changes
across time (p = 0.46). Cortisol levels tended to change
over time (p = 0.093). Serum cortisol levels were signifi-
cantly different between groups over time (p = 0.029) and
revealed how supplementation caused significant variabil-
ity (p = 0.032) in cortisol changes from pre-lift levels
across the recovery period. Serum cortisol levels increased
on average 13 % over pre-lift values during the recovery in
P, but only 8 % in TC. The delta post-hoc analysis revealed
that TC cortisol levels were not different from pre-lift
levels and were significantly lower at 48-h post-lift com-
pared to rising cortisol levels in P (see Fig. 5).
Markers of free radical production and oxidative stress
Table 7 reports the serum markers of free radical produc-
tion [reactive oxygen species (ROS) and reactive nitrogen
species (RNS)] analyzed in response to exercise. The over-
all MANOVA analysis revealed no significant overall
Wilks’ Lambda time (p = 0.32) interaction and no overall
group differences over time (p = 0.76). None of the uni-
variate measures for markers of free radical production,
lipid peroxidation, and antioxidant capacity/activity (NT,
TBARS, TAS, and SOD) reported main time effects or dif-
ferences between groups over time.
Inflammatory response markers
Table 8 shows the serum inflammatory cytokine and che-
mokine markers analyzed in response to exercise. The
overall MANOVA analysis revealed a significant overall
Wilks’ Lambda time (p < 0.001) interaction, but a non-
significant overall group x time effect (p = 0.30). Univariate
measures for TNF-α (p = 0.001), IL-1β (p = 0.030), IL-6
(p = 0.023), and IL-8 (p = 0.018) demonstrated signifi-
cant changes over time and from baseline measures,
peaking 24-h post-lift. No significant differences between
groups were observed over time for any of the inflamma-
tory cytokines or chemokines.
Anti-inflammatory response markers
Table 9 presents the serum anti-inflammatory cytokine
markers analyzed in response to exercise. The overall
MANOVA analysis revealed a significant overall Wilks’
Lambda time (p < 0.001) interaction, but a non-significant
overall effect of treatment over time (p = 0.45). Univariate
measures for IL-4 (p = 0.001) and IL-7 (p = 0.033) reported
significant main time effects with IL-13 levels approaching
significance across time (p = 0.055), peaking 60-min post-
lift. No significant group effects over time were reported
for any of the anti-inflammatory cytokine markers.
Clinical markers of immune-related complete blood
counts
Table 10 displays immune response-related complete
blood count markers analyzed in response to exercise.
The overall MANOVA analysis demonstrated significant
overall Wilks’ Lambda time interaction (p < 0.001), but a
non-significant overall difference between groups over
time (p = 0.68). Univariate measures for lymphocytes
(p < 0.001) and MID (p < 0.001) demonstrated signifi-
cant changes over time and from baseline measures,
most depressed 60-min post-lift. WBC (p = 0.004) and
GRAN (p = 0.003) also significantly changed over time,
with lowest values 48-h post-lift. MID levels tended to
be different between groups over time (p = 0.062). Signifi-
cant group changes over time (p = 0.015) and differences in
group effects from pre-lift levels over the recovery period
(p = 0.013) were reported for lymphocytes. Lymphocyte
levels decreased on average 23 % below pre-lift values dur-
ing the recovery in P, but only 11 % in TC. Subsequent
post-hoc analysis showed a significantly greater lymphocyte
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Table 5 Markers of Muscle Catabolism, Secondary Muscle Damage, and Physiological Stress
Variable Group Baseline Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
AST (U/L) P 31.85±9.65 27.47±6.40 30.79±7.88 41.39±13.31 37.67±10.33 33.83±2.19 G=0.919
TC 37.70±17.65 28.39±7.62 29.53±6.46 40.59±17.59 31.32±11.57 33.51±2.29 T=0.003* Tq=0.759
Time Mean 34.78±2.93 27.93±1.46† 30.16±1.51Ψ 40.99±3.23Ψ◊ 34.50±2.28Ψ# G X T=0.316 G X TL=0.162
ALT (U/L) P 33.81±18.74 32.21±12.26 34.19±13.60 36.78±14.97 35.80±13.84 34.56±4.19 G=0.455
TC 31.78±13.22 30.01±19.33 28.32±15.83 31.08±19.58 28.54±17.41 29.94±4.38 T=0.529 TL=0.180
Time Mean 32.79±3.41 31.11±3.34 31.26±3.07 33.93±3.61Ψ◊ 32.17±3.27 G X T=0.521 G X TL=0.266
Total Billirubin (umol/L) P 8.00±3.67 7.25±3.47 9.08±5.31 8.14±3.82 7.35±3.21 7.96±1.01 G=0.395
TC 9.65±3.85 9.98±4.95 9.58±4.01 9.79±5.20 7.19±3.21 9.24±1.06 T=0.064§ Tq=0.026*
Time Mean 8.83±0.78 8.61±0.89 9.33±0.99 8.97±0.95 7.27±0.67†Ψ◊# G X T=0.306 G X TL=0.125
Urea/BUN (mmol/L) P 6.59±1.54 6.16±1.74 6.07±1.59 6.48±1.96 5.92±2.33 6.24±0.44 G=0.794
TC 6.49±1.39 6.75±1.30 6.40±1.33 6.59±1.83 5.83±1.66 6.41±0.46 T=0.061§ TL=0.055
§
Time Mean 6.54±0.31 6.46±0.32 6.24±0.31 6.53±0.40 5.88±0.43†Ψ# G X T=0.594 G X Tq=0.238
Creatinine (umol/L) P 96.50±13.23 97.19±19.28 102.76±17.25^ 98.91±21.16^ 95.20±17.73^◊ 98.11±4.05 G=0.273
TC 91.82±11.99 96.84±15.27 95.42±14.37 91.52±11.27 81.99±14.87†Ψ◊# 91.52±4.23 T=0.004* Tq=0.003*
Time Mean 94.16±2.64 97.02±3.65 99.09±3.33 95.21±3.58 88.60±3.43†Ψ◊# G X T=0.178 G X TL=0.030*
BUN/Creatinine Ratio P 17.11±4.38 15.97±3.99 14.82±3.66 16.66±5.67 15.50±5.26 16.01±1.08 G=0.353
TC 17.65±3.76 17.51±3.83 16.82±3.74 17.85±4.35 17.64±3.80 17.50±1.13 T=0.214 Tq=0.225
Time Mean 17.37±4.01 16.71±3.90 15.78±3.75†Ψ 17.23±5.00 16.53±4.64 G X T=0.721 G X TL=0.388
Uric Acid (umol/L) P 328±66 317±66 444±136 367±80 349±88 361.12±20.37 G=0.647
TC 306±52 310±54 470±117 350±93 302±79 347.44±21.28 T<0.001* Tq<0.001*
Time Mean 317±12 314±13 457±27†Ψ 358±18†Ψ◊ 325±17◊# G X T=0.298 G X Tq=0.146
CK (U/L) P 468±288 322±243 451±267 967±700 855±981 613±82 G=0.487
TC 843±1156 259±146 355±198 770±470 415±213 529±86 T=0.025* Tq=0.222
Time Mean 656±172 291±42† 403±49Ψ 869±126Ψ◊ 635±151Ψ G X T=0.209 G X TL=0.100
§
Total Protein (mmol/L) P 78.67±6.11 67.55±7.96^† 72.23±6.47†Ψ 68.67±9.45† 73.67±11.11†Ψ# 72.16±1.52 G=0.305
TC 80.53±4.60 74.13±2.62† 74.59±4.18† 72.43±6.72† 70.66±7.92†Ψ◊ 74.47±1.59 T<0.001* Tq<0.001*
Time Mean 79.60±1.14 70.84±1.26† 73.41±1.15†Ψ 70.55±1.72† 72.17±2.03† G XT=0.091§ G X Tq=0.018*
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents the response to muscle catabolism, mechanical damage, and physiological stress at each
test session during the 10 day intervention. MANOVA analysis revealed overall Wilks' Lambda time (p<0.001) and group x time (p=0.504). Univariate ANOVA p-levels from MANOVA analysis are presented for each
variable. Univariate ANOVA p-levels are listed first by the Greenhouse-Geisser (GG) analysis and then by the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x time interaction
with significance indicated by the following super/subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD post hoc analysis is indicated by the following superscripts: ^ represents
p<0.05 difference between groups, † represents p<0.05 difference from baseline value, Ψ represents p<0.05 difference from pre-lift, ◊ represents p<0.05 difference from 60-min post, # represents p<0.05 difference
from 24-hr post. AST Aspartate aminotransferase, ALT Alanine aminotransferase, BUN blood urea nitrogen, CK Creatine kinase, G group p-level, T time p-level, G x T interaction, q quadratic p-level, L linear p-level
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counts 24-h and 48-h post-lift in TC compared to P, but
unlike those supplementing with P, TC lymphocyte counts
returned to pre-lift values by the end of the recovery (48-h
post-lift). A significant group effect over time was also re-
ported for WBC (p = 0.020). WBC decreased on average
8 % below pre-lift values during the recovery in P, but only
3 % in TC. Post-hoc analysis demonstrated significant
WBC differences pre-lift, 24-h, and 48-h post-lift between
TC and P that became insignificant once changes were
calculated from pre-lift levels.
Discussion
This is the first study to investigate the effect of freeze
dried Montmorency tart cherry skin powder on acute re-
sistance exercise performance and recovery. It was hypoth-
esized that supplementation with this novel powdered tart
Fig. 4 Markers of protein catabolism. Data expressed as means ± SE and significance indicated by the following super/subscripts: * indicates p < 0.05
p-level significance, § indicates p< 0.10 p-level significance. LSD post hoc analysis is indicated by the following superscripts: ^ represents p< 0.05 difference
between groups, Ψ represents p< 0.05 difference from pre-lift, ◊ represents p< 0.05 difference from 60-min post, # represents p< 0.05 difference from
24-h post
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cherry skin supplement surrounding an acute bout of
intense resistance exercise would reduce perceptions of
muscle soreness, markers of muscle damage, oxidative
stress, and inflammation, thus better maintaining subse-
quent performance within the first 48-h of recovery. The
results of the present study demonstrate that this powered
tart cherry formulation is effective in promoting decreased
perceptions of muscle soreness following intense resistance
exercise. Tart cherry powder reduced perceptions of
muscle soreness in the distal vastus medalis and lateralis.
In accordance with decreased perceptions of muscle sore-
ness, tart cherry powder supplementation reduced serum
markers of muscle catabolism and physiological stress over
the 48-h post-lift period compared to placebo. As a result
of the resistance exercise, markers of oxidative stress, lipid
peroxidation, and antioxidant activity did not significantly
change over time as was not affected by differences in sup-
plementation. The inflammatory response deviated from
Fig. 5 Markers of physiological stress and secondary indices of muscle damage. Data expressed as means ± SE and significance indicated by the
following super/subscripts: * indicates p < 0.05 p-level significance, § indicates p < 0.10 p-level significance. LSD post hoc analysis is indicated by
the following superscripts: ^ represents p < 0.05 difference between groups, Ψ represents p < 0.05 difference from pre-lift, ◊ represents p < 0.05
difference from 60-min post, # represents p < 0.05 difference from 24-h post
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Table 6 Anabolic/Catabolic Hormone Response
Variable Group Baseline Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
Cortisol (ug/dL) P 28.34±13.07^ 23.33±8.80 26.37±7.33 25.08±10.21^ 27.68±11.20^ 26.16±2.18 G=0.167
TC 21.48±7.02 20.49±7.92 26.81±12.08† 19.72±5.56◊ 19.74±6.82◊ 21.65±2.28 T=0.093§ TL=0.611
Time Mean 24.91±2.22 21.91±1.75 26.59±2.06Ψ 22.40±1.74◊ 23.71±1.96 G X T=0.170 G X Tq=0.029*
Testosterone (ng/mL) P 9.86±3.46 9.37±3.45 9.25±2.92 10.17±3.55 9.94±3.42 9.72±0.75 G=0.025*
TC 7.24±2.22 7.17±2.00 6.97±1.95 7.20±2.00 6.91±1.70 7.10±0.79 T=0.428 Tq=0.427
Time Mean 8.55±0.61 8.27±0.60 8.11±0.52 8.68±0.61 8.42±0.57 G X T=0.556 G X TL=0.174
Test/Cort Ratio P 0.037±0.009 0.043±0.014 0.037±0.013 0.045±0.019 0.040±0.018 0.040±0.003 G=0.538
TC 0.037±0.015 0.040±0.020 0.031±0.015 0.039±0.013 0.040±0.019 0.037±0.004 T=0.152 TL=0.516
Time Mean 0.037±0.012 0.042±0.017 0.034±0.014 0.042±0.016 0.040±0.018 G X T=0.815 G X Tq=0.196
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents the stress and sex hormone response at each test session during the 10 day intervention.
MANOVA analysis revealed overall Wilks' Lambda time (p=0.293) and group x time (p=0.458). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. Univariate ANOVA p-levels are listed
first by the Greenhouse-Geisser (GG) analysis and then by the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x time interaction with significance indicated by the following
super/subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD post hoc analysis is indicated by the following superscripts: ^ represents p<0.05 difference between groups, †
represents p<0.05 difference from baseline value, Ψ represents p<0.05 difference from pre-lift, ◊ represents p<0.05 difference from 60-min post, # represents p<0.05 difference from 24-hr post. Test/Cort =
Testosterone/Cortisol ratio G group p-level, T time p-level, G x T interaction, q quadratic p-level; L = linear p-level
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pre-lift values during the recovery period, but the change
was not different between supplement groups.
The attenuation of quadriceps muscle soreness in con-
junction with reduced hemodynamic markers of muscle
catabolism following the resistance training bout indi-
cates that the consumption of tart cherry powder may
have dampened the effects of the secondary muscle
damage response. The initial injury to the muscle micro-
structure is defined by a mechanical disruption of the
myofibrils, particularly in response to high volume and
intensity eccentric exercise [9, 44, 56]. The damage to
the muscle microstructure triggers a local inflammatory
response characterized by infiltration of fluid, plasma
proteins, and free radicals that all exacerbate the initial
mechanical muscle damage, creating a secondary injury
incidence [9, 44, 57–60]. Decreased perceptions of quad-
riceps muscle soreness and muscle catabolism indices
reveal that supplementation with powdered tart cherry
may aid in blunting the secondary muscle damage ef-
fects compared to placebo.
The apparent beneficial effect of tart cherry powder sup-
plementation on the perception of muscle soreness after a
resistance exercise bout is consistent with some of the
previously published findings. Connolly et al. [20] reported
that consumption of a Montmorency tart cherry juice in
healthy college-aged males significantly reduced pain in
the elbow flexors after a bout of eccentric exercise using a
visual analog scale (VAS). Peak muscle pain was achieved
24-h post-exercise in the tart cherry group compared to a
continued increase in pain 48-h post-exercise in the
placebo group. In contrast, Connolly et al. [20] reported
no difference in pressure pain threshold (PPT) scores
between the two experimental groups. Using a strenuous
single leg knee extension protocol in a cohort of well-
trained male athletes, Bowtell et al. [4] demonstrated a
trend in post-exercise muscle pain reduction via PPT with
Montmorency tart cherry juice supplementation up to 48-
h post-exercise compared to placebo. The positive results
in the current study are similar to previous tart cherry
supplementation research findings, showing that pow-
dered tart cherry supplementation significantly attenuates
muscle soreness perceptions throughout the 48-h post-lift
recovery compared to placebo. Slight differences in
study outcomes may lie in the disparity of muscle pain
or soreness measures, tart cherry supplements, quantity
of musculature involvement, and/or exercise modality.
Measurement of muscle soreness perception in the
present study utilizing both an algometer and a GRPS was
implemented to help ameliorate the purely subjective
nature of a VAS as the only measure of pain or soreness.
The attenuation in post-lift muscle soreness with pow-
dered tart cherry supplementation may be described by
underlying catabolic mechanisms. Similar to the results of
the current study, Bowtell et al. [4], following exhaustive
leg extension exercise, demonstrated a faster post-exercise
recovery of knee extensor force coupled with a trend for a
Table 7 Markers of Free Radical Production and Oxidative Stress
Variable Group Baseline Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
Nitrotyrosine (nM) P 305±267 306±311 297±289 297±330 294±305 300±74 G=0.940
TC 303±193 319±254 277±190 275±202 283±203 292±78 T=0.280 TL=0.146
Time Mean 304±230 312±279 288±241 287±270 289±256Ψ G X T=0.613 G X TL=0.483
TBARS (uM) P 7.84±2.69 7.27±2.91 8.60±2.67 8.03±3.34 8.43±3.74 8.03±0.81 G=0.913
TC 7.74±4.24 8.24±4.03 7.44±3.84 8.19±3.46 7.91±3.35 7.90±0.84 T=0.937 TL=0.539
Time Mean 7.79±3.44 7.73±3.44 8.05±3.26 8.10±3.32 8.18±3.49 G X T=0.569 G X TL=0.649
TAS (mM) P 2.90±1.34 2.83±1.77 3.02±1.85 2.95±1.47 2.80±1.81 2.90±0.39 G=0.752
TC 2.69±1.17 2.39±1.14 2.99±1.07 2.73±1.36 2.81±1.34 2.72±0.41 T=0.323 Tq=0.419
Time Mean 2.80±1.23 2.62±1.48 3.01±1.49 2.84±1.39 2.81±1.57 G X T=0.706 G X TL=0.442
SOD (U/mL) P 0.58±0.07 0.59±0.05 0.59±0.09 0.56±0.08 0.58±0.06 0.58±0.02 G=0.668
TC 0.55±0.12 0.60±0.09 0.54±0.09 0.57±0.10 0.57±0.11 0.57±0.02 T=0.264 Tq=0.827
Time Mean 0.56±0.10 0.60±0.07† 0.57±0.09 0.57±0.08 0.58±0.09 G X T=0.335 G X TL=0.784
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents the response to reactive oxygen
and nitrogen species production in addition to antioxidant activity at each test session during the 10 day intervention. MANOVA analysis revealed overall Wilks'
Lambda time (p=0.321) and group x time (p=0.756). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. Univariate ANOVA p-levels
are listed first by the Greenhouse-Geisser (GG) analysis and then by the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x
time interaction with significance indicated by the following super/subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD
post hoc analysis is indicated by the following superscripts: ^ represents p<0.05 difference between groups, † represents p<0.05 difference from baseline value, Ψ
represents p<0.05 difference from pre-lift, ◊ represents p<0.05 difference from 60-min post, # represents p<0.05 difference from 24-hr post
TBARS Thiobarbituric acid reactive substances, TAS Total antioxidant status, SOD superoxide dismutase, G group p-level, T time p-level, G x T interaction, q
quadratic p-level, L linear p-level
Levers et al. Journal of the International Society of Sports Nutrition  (2015) 12:41 Page 16 of 23
smaller CK percent change from pre-exercise levels up to
48-h post-exercise with tart cherry supplementation com-
pared to placebo [43]. Following a treadmill incremental ex-
ercise protocol with thoroughbred horses, Ducharme et al.
[61] reported an attenuation trending toward significance
in CK levels during exercise recovery when supplementing
with a tart cherry juice blend compared to placebo. Similar
to the post-lift attenuations of ALT (60-min and 48-h post)
and AST (48-h post) as secondary markers of muscle dam-
age in the current study, Ducharme et al. [61] reported that
AST was significantly mitigated during and following an
incremental exercise protocol in the tart cherry-treated
horses compared to placebo [43]. In an endurance-based
crossover study examining the effects of acute ibuprofen
(8400 mg) ingestion surrounding a 45-min downhill tread-
mill run, Donnelly et al. [62] reported an increase in serum
CK, AST, and lactate dehydrogenase post-run with max-
imal activity of CK and AST occurring at 24-h post-run,
while lactate dehydrogenase, creatinine, and urea peaked
6-h post-run. Donnelly et al. [62] revealed that serum CK
and urea levels were significantly higher after ibuprofen
supplementation compared to placebo throughout the
post-run recovery. Analyzing hemodynamic clinical chem-
istry makers before, 4-h, and 24-h post-Boston marathon,
Kratz et al. [63] reported significant increases in total CK,
AST, ALT, total protein, uric acid, and creatinine 4-h post-
race and confirmed that CK, creatinine, uric acid, ALT,
and AST remained significantly elevated over pre-race
values 24-h post-race. The attenuation of these markers in
the current study, demonstrates beneficial powdered tart
cherry supplementation effects on the post-resistance
exercise catabolic, muscle damage, and stress response.
Acute, intensive resistance exercise (>60 % 1-RM) has
been reported to significantly increase muscular mech-
anical trauma as the initial phase of injury [4, 64]
coupled with a secondary inflammatory injury phase that
Table 8 Pro-inflammatory Cytokines and Chemokines
Variable Group Baseline Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
TNF-α (pg/mL) P 2.82±1.33 3.30±1.59 3.33±1.88 2.98±1.45 2.85±1.41 3.05±0.36 G=0.212
TC 2.12±0.92 2.55±1.15 2.61±1.00 2.44±0.82 2.23±0.94 2.39±0.37 T=0.003* Tq=0.001*
Time Mean 2.47±0.24 2.92±0.29† 2.97±0.32† 2.71±0.25◊ 2.54±0.25Ψ◊ G X T=0.873 G X TL=0.649
IFN-γ (pg/mL) P 14.92±31.51 18.91±44.08 18.99±44.51 21.33±51.78 21.56±51.82 19.14±9.41 G=0.365
TC 6.19±5.69 6.46±5.01 7.12±5.19 7.11±5.98 5.78±6.02 6.53±9.83 T=0.287 Tq=0.136
Time Mean 10.56±4.83 12.68±6.70 13.06±6.77 14.22±7.87 13.67±7.88# G X T=0.314 G X TL=0.295
IL-1β (pg/mL) P 0.77±0.32 0.84±0.35 0.87±0.39 0.83±0.38 0.83±0.35 0.83±0.10 G=0.048*
TC 0.75±0.35 0.75±0.34 0.82±0.26 0.85±0.30 0.82±0.34 0.80±0.10 T=0.047* Tq=0.030*
Time Mean 0.76±0.07 0.80±0.07† 0.85±0.07† 0.84±0.07 0.82±0.07 G X T=0.411 G X Tq=0.488
IL-2 (pg/mL) P 1.86±1.86 2.00±2.18 1.97±2.16 1.91±2.15 1.87±2.09 1.92±0.71 G=0.956
TC 1.70±2.96 1.73±2.73 2.06±2.65 2.26±3.13 2.15±3.03 1.98±0.74 T=0.292 TL=0.214
Time Mean 1.78±0.51 1.87±0.51 2.02±0.50 2.08±0.56 2.01±0.54 G X T=0.230 G X TL=0.163
IL-6 (pg/mL) P 1.19±0.95 1.34±1.36 1.61±1.60 1.33±1.38 1.26±1.21 1.35±0.37 G=0.724
TC 0.87±1.34 1.09±1.31 1.54±1.38 1.20±1.49 1.07±1.43 1.16±0.39 T=0.020* Tq=0.023*
Time Mean 1.03±0.24 1.22±0.28 1.57±0.31†Ψ 1.27±0.30† 1.17±0.28◊# G X T=0.761 G X TL=0.512
IL-8 (pg/mL) P 4.25±3.99 5.07±5.74 5.04±6.16 5.16±6.41 4.94±6.32 4.89±1.23 G=0.496
TC 2.95±1.56 3.45±1.75 4.14±1.29 4.02±1.78 3.74±1.91 3.66±1.28 T=0.042* Tq=0.018*
Time Mean 3.60±0.64 4.26±0.90† 4.59±0.95† 4.59±1.00 4.34±0.99 G X T=0.697 G X TL=0.736
IL-12p70 (pg/mL) P 2.27±4.13 3.03±6.51 3.05±6.63 3.01±6.42 2.78±5.68 2.83±1.33 G=0.577
TC 1.70±2.67 1.76±2.59 1.68±2.15 1.91±2.76 1.66±2.61 1.74±1.39 T=0.279 Tq=0.264
Time Mean 1.99±0.73 2.39±1.05 2.37±1.05 2.46±1.05 2.22±0.94 G X T=0.377 G X TL=0.351
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents the pro-inflammatory response at
each test session during the 10 day intervention. MANOVA analysis revealed overall Wilks' Lambda time (p<0.001) and group x time (p=0.302). Univariate ANOVA
p-levels from MANOVA analysis are presented for each variable. Univariate ANOVA p-levels are listed first by the Greenhouse-Geisser (GG) analysis and then by
the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x time interaction with significance indicated by the following super/
subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD post hoc analysis is indicated by the following superscripts: ^
represents p<0.05 difference between groups, † represents p<0.05 difference from baseline value, Ψ represents p<0.05 difference from pre-lift, ◊ represents
p<0.05 difference from 60-min post, # represents p<0.05 difference from 24-hr post
TNF-α tumor necrosis factor alpha, IFN-γ interferon gamma, IL interleukin, G group p-level, T time p-level, G x T interaction, q quadratic p-level, L linear p-level
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occurs as a result of plasma protein and inflammatory cell
infiltration of the damaged tissue [4, 9, 57]. Howatson et
al. [44] reported significantly lower IL-6 concentrations
after running a marathon that coincided with quicker
recovery of knee extensor maximal strength following the
marathon in Montmorency tart cherry juice supplemented
subjects compared to placebo [44]. As an inflammatory
marker, IL-6 was significantly attenuated immediately
post-race with tart cherry consumption compared to pla-
cebo [43, 44]. In a strength-based supplement study with
resistance trained subjects, Bowtell et al. [4] was also not
able to detect any significant effects on IL-6 as a marker
of inflammation. Further, Trombold et al. [65] reported
similar non-significant inflammatory (IL-6) findings in a
study involving non-resistance trained subjects perform-
ing repeated bouts of eccentric elbow flexor muscle con-
tractions with consumption of pomegranate-derived
ellagitannin [4]. Supplementation in the current study did
not affect the inflammatory response to muscular trauma
as markers peaked 60-min post-lift with no response dif-
ferences between supplementation groups. Attenuation of
muscle soreness perceptions and markers of muscle dam-
age are not likely attributed to changes in inflammation
following a single resistance exercise bout. Differences in
results between studies are likely attributed to variation in
intensity, duration, and modality of the aforementioned
exercise protocols.
The increase in inflammatory-related cytokines and
chemokines such as TNF-α, IL-1β, IL-6, and IL-8 during
and immediately following exercise has been shown in
previous research [66–68] and closely resembles the in-
flammatory response in the current study. As described
in previous literature, the increase in serum IL-6 within
both groups 60-min post-lift in the current study can
likely be attributed to the large release of muscle-derived
IL-6 as a result of the contracting muscle fibers [66, 69].
The influx of muscle-derived IL-6 within the systemic
circulation may be one of the triggers for subsequent
cortisol release in response to exercise-induced stress
[66, 70]. Glucocorticoids, specifically cortisol, and anti-
inflammatory cytokines such as IL-4, IL-10, and IL-13
are released during strenuous exercise and typically
demonstrate an immunosuppressive influence to help
modulate the immune response balance [71]. However,
extended immunodepression due to elevated plasma
cortisol during the post-exercise period, particularly fol-
lowing long bouts of intense training in the fasted state
[66], may hinder recovery and subsequent performance.
Previous research conducted by McAnulty et al. [72] in
trained endurance athletes reported a significant cortisol
Table 9 Anti-inflammatory Cytokines
Variable Group Baseline Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
IL-4 (pg/mL) P 6.03±3.18 7.86±5.06 8.26±5.22 7.44±4.95 7.83±5.10 7.48±1.05 G=0.273
TC 4.16±1.91 5.45±2.04 6.38±2.49 6.36±2.45 6.54±3.01 5.78±1.09 T=0.001* Tq=0.001*
Time Mean 5.10±0.55 6.65±0.82† 7.32±0.87† 6.90±0.83†◊ 7.19±0.88† G X T=0.421 G X TL=0.405
IL-5 (pg/mL) P 0.69±0.37 0.70±0.41 0.70±0.46 0.64±0.37 0.65±0.40 0.68±0.11 G=0.749
TC 0.75±0.43 0.72±0.40 0.71±0.37 0.77±0.43 0.70±0.42 0.73±0.12 T=0.716 TL=0.325
Time Mean 0.72±0.08 0.71±0.09 0.70±0.09 0.71±0.08 0.68±0.09 G X T=0.438 G X TL=0.582
IL-7 (pg/mL) P 4.73±2.19 5.41±2.49 5.94±3.71 5.52±2.75 5.46±2.57 5.41±0.63 G=0.414
TC 4.15±1.86 4.45±2.00 5.31±2.18 4.91±1.61 4.47±1.54 4.66±0.65 T=0.041* Tq=0.033*
Time Mean 4.44±0.43 4.93±0.48† 5.62±0.64† 5.21±0.48† 4.97±0.45† G X T=0.843 G X TL=0.757
IL-10 (pg/mL) P 4.52±3.85 3.69±1.82 4.21±1.92 3.48±1.70 3.45±1.74 3.87±0.56 G=0.869
TC 2.77±1.74 3.49±2.03 6.02±5.70 3.33±2.54 3.07±2.54 3.74±0.59 T=0.103§ Tq=0.157
Time Mean 3.65±0.63 3.59±0.40 5.12±0.87Ψ 3.41±0.45 3.26±0.45 G X T=0.182 G X Tq=0.120
IL-13 (pg/mL) P 3.30±2.89 3.33±3.30 3.40±3.48 3.24±3.64 3.27±3.56 3.31±0.78 G=0.449
TC 1.96±1.74 2.26±1.66 2.75±2.09 2.78±2.18 2.45±2.34 2.44±0.81 T=0.393 Tq=0.055
§
Time Mean 2.63±0.50 2.80±0.55 3.08±0.61 3.01±0.63 2.86±0.64 G X T=0.402 G X Tq=0.133
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents the anti-inflammatory response at
each test session during the 10 day intervention. MANOVA analysis revealed overall Wilks' Lambda time (p<0.001) and group x time (p=0.447). Univariate ANOVA
p-levels from MANOVA analysis are presented for each variable. Univariate ANOVA p-levels are listed first by the Greenhouse-Geisser (GG) analysis and then by
the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x time interaction with significance indicated by the following super/
subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD post hoc analysis is indicated by the following superscripts: ^
represents p<0.05 difference between groups, † represents p<0.05 difference from baseline value, Ψ represents p<0.05 difference from pre-lift, ◊ represents
p<0.05 difference from 60-min post, # represents p<0.05 difference from 24-hr post
IL interleukin, G group p-level, T time p-level, G x T interaction, q quadratic p-level, L linear p-level
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Table 10 Markers of Immune-Related Complete Blood Counts
Variable Group Baseline Pre-Lift 60-min Post 24-hr Post 48-hr Post Group Mean p-value (GG) p-value (WSC)
LYMPH (K/uL) P 1.93±0.54 2.21±0.69 1.45±0.43†Ψ 1.86±0.71^Ψ◊ 1.78±0.48^Ψ◊ 1.85±0.20 G=0.311
TC 2.09±0.86 2.36±1.05† 1.49±0.58†Ψ 2.62±1.51†Ψ◊ 2.15±0.78◊# 2.14±0.21 T<0.001* Tq=0.136
Time Mean 2.01±0.15 2.28±0.18† 1.47±0.11†Ψ 2.24±0.24◊ 1.97±0.13Ψ◊ G X T=0.143 G X TL=0.015*
WBC (K/uL) P 5.88±1.23 6.61±2.21^ 6.38±1.45 6.16±1.62^ 5.75±1.61^ 6.16±0.40 G=0.337
TC 5.54±1.25 7.18±2.03† 6.98±2.04† 7.40±2.17† 6.55±1.23†# 6.73±0.42 T=0.004* Tq=0.004*
Time Mean 5.71±0.26 6.90±0.44† 6.68±0.37† 6.78±0.40† 6.15±0.30Ψ G X T=0.207 G X TL=0.020*
MID (K/uL) P 0.43±0.12 0.64±0.19 0.43±0.14 0.53±0.13 0.48±0.13 0.50±0.03 G=0.866
TC 0.42±0.10 0.61±0.24 0.38±0.10 0.60±0.19 0.55±0.16 0.51±0.03 T<0.001* TL=0.100
§
Time Mean 0.43±0.02 0.63±0.05† 0.41±0.03Ψ 0.56±0.03†◊ 0.51±0.03†Ψ◊ G X T=0.324 G X TL=0.062
§
GRAN (K/uL) P 3.50±0.97 3.76±1.47 4.51±1.20 3.78±1.33 3.48±1.32 3.80±0.33 G=0.577
TC 3.04±0.48 4.22±1.77 5.11±2.35 4.17±1.61 3.84±0.98 4.08±0.35 T<0.001* Tq=0.002*
Time Mean 3.27±0.16 3.99±0.34† 4.81±0.38†Ψ 3.97±0.31†◊ 3.66±0.03◊ G X T=0.332 G X TL=0.119
GM-CSF (pg/mL) P 8.12±8.23 8.18±8.33 7.87±7.38 7.54±7.67 7.39±7.49 7.82±2.71 G=0.512
TC 10.37±11.40 10.51±10.83 10.52±10.48 10.67±11.19 10.09±10.89 10.43±2.83 T=0.446 TL=0.277
Time Mean 9.24±2.06 9.34±2.00 9.20±1.88 9.10±1.99 8.74±1.93 G X T=0.624 G X TL=0.450
Individual group and time data expressed as means ± SD, while group effects are presented as means ± SEM. Data represents immune cellular response markers at each test session during the 10 day intervention.
MANOVA analysis revealed overall Wilks' Lambda time (p<0.001) and group x time (p=0.684). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. Univariate ANOVA p-levels are listed
first by the Greenhouse-Geisser (GG) analysis and then by the within-subjects contrasts (WSC) to demonstrate the potential shape of the time or group x time interaction with significance indicated by the following
super/subscripts: * indicates p<0.05 p-level significance, § indicates p<0.10 p-level significance. LSD post hoc analysis is indicated by the following superscripts: ^ represents p<0.05 difference between groups, †
represents p<0.05 difference from baseline value, Ψ represents p<0.05 difference from pre-lift, ◊ represents p<0.05 difference from 60-min post, # represents p<0.05 difference from 24-hr post
LYMPH lymphocytes, WBC white blood cell, MID mid-range absolute count, GRAN granulocyte absolute count, GM-CSF granulocyte-macrophage colony-stimulating factor, G group p-level, T time p-level, G x T
interaction, q quadratic p-level, L linear p-level
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increase over time, but no significant differences in imme-
diate and 1.5-h post-race cortisol levels with 2-month vita-
min E supplementation compared to placebo. Comparing
14-d supplementation of N-acetyl-cysteine (NAC), epi-
gallocatechin gallate (EGCG), or a placebo in active males
surrounding a single bout of eccentric knee-extensor exer-
cise, Kerksick et al. [73] found a significant decrease in
serum cortisol levels 6-h post-exercise, but no differences
between groups up to 72-h post-exercise despite a signifi-
cant blunting of muscle soreness perception 24-h post ex-
ercise in the two supplement groups compared to placebo.
The current study demonstrated an increase in cortisol
levels 60-min post-lift compared to pre-lift in both groups.
However, unlike the cortisol and muscle soreness percep-
tion results reported by Kerksick et al. [73], the current
study demonstrated significantly elevated cortisol levels
and muscle soreness in the placebo group compared to
the powdered tart cherry group 24-h and 48-h post-lift.
The placebo group elevations in serum cortisol levels
in the latter recovery period may be linked to differences
in the immune response and the degree of secondary
muscle injury. Previous research by McCarthy et al. [74]
and Robson et al. [75] demonstrate that in response to
repetitive muscular contraction during and immediately
after acute, intense exercise, there is a large increase in
circulating neutrophils (GRAN) and lymphocytes. Ac-
cording to data collected by Robson et al. [75], plasma
neutrophil levels tend to peak 2–3 hours post-exercise,
but remain elevated above pre-exercise levels for up to
10-h post-exercise due to elevations in plasma cortisol
(e.g. perception of stress) that facilitate the release of
neutrophils from the bone marrow. The current study
demonstrated a plasma neutrophil (GRAN) peak 60-min
post-lift, but effects of supplementation could not be
determined as levels returned to pre-lift concentrations
by 24-h. Unlike the neutrophil response to acute exer-
cise, lymphocytes respond in a biphasic pattern, where
plasma levels are significantly elevated during and im-
mediately post-exercise followed by a drop below pre-
exercise levels during the initial recovery period due to a
efflux from the blood circulation, and a slow return to
baseline levels as equilibrium is reached again [71, 75].
Robson et al. [75] demonstrated that serum cortisol
levels influence both the influx of neutrophils and efflux
of lymphocytes from systemic circulation. The results of
the current study demonstrated that lymphocyte levels
in the placebo group never returned to pre-lift levels
during the 48-h recovery. This may be linked to the ele-
vated plasma cortisol levels in the placebo group repre-
senting an increased physiological perception of exercise
stress 48-h post-lift compared to pre-lift and powdered
tart cherry group levels. As previously mentioned, the
secondary injury phase occurs as a result of significant
plasma protein and inflammatory cell influx within the
damaged tissue [4, 9, 57]. Powdered tart cherry supple-
mentation may have aided in reducing secondary mus-
cular injury through an initial dampening of the immune
response paired with the attenuated cortisol response
later in exercise recovery. However, immune cell count
changes in response to supplementation and the resist-
ance exercise stimulus are speculative due to the lack of
cellular count data corresponding to typical patterns of
immune cell responses during and immediately follow-
ing the barbell back squat challenge.
The increase in antioxidant bioavailability from tart
cherries containing high levels of flavonoids and antho-
cyanins [76, 77] has been hypothesized to be one of the
main benefits of tart cherry supplementation. Antioxi-
dant bioavailability is important in maintaining adequate
redox balance to support the endogenous antioxidant
systems following excessive ROS-producing strenuous
exercise. Ducharme et al. [61] investigated the effects of
Montmorency tart cherry juice supplementation on oxi-
dative stress in thoroughbred horses following a stepwise
incremental treadmill running protocol [43]. Overall in-
dications of oxidative stress as a result of exercise were
reported through significant elevations in lipid hydroper-
oxidation (TBARS) [61], but similar to the current study,
no differences between groups were shown. In an endur-
ance study examining the effects of tart cherry juice sup-
plementation on oxidative stress following a marathon
run, Howatson et al. [44] demonstrated significantly lower
TBARS levels in the tart cherry supplemented group
versus placebo 48-h post-marathon. As a highly reactive
oxide metabolite of nitric oxide, peroxynitrate-bound tyro-
sine residues forming nitrotyrosine (NT) [78] were mea-
sured by Sureda et al. [79] following supplementation of
vitamin C + E surrounding a half-marathon. Suerda et al.
[79] reported a significant increase in both NT immedi-
ately post-race and 3-h post-race in the placebo group
compared to the vitamin C + E supplemented group, indi-
cating that antioxidant supplementation may have an
attenuating effect on the oxidation of nitrogen-containing
compounds surrounding endurance exercise. Contrarily,
both Bowtell et al. [4] and the current study found no dif-
ference between supplementation groups with regard to
oxidation of nitric oxide (NT) in the post-strength exercise
period. A difference in outcome may be attributable to the
difference in exercise modality and thus the minimal reli-
ance on aerobic metabolic demands during resistance
exercise. Further, evidence in the literature utilizing lipid
peroxidation (TBARS) analyses have presented a potential
lack of oxidative damage detection specificity in human
studies that may also explain the variability in results
between the current and previous studies [11, 43, 80, 81].
In a study analyzing the recovery from a marathon
run, Howatson et al. [44] analyzed plasma TAS, as a
measure of antioxidant or antiradical activity [82], and
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found that TAS fell below baseline 48-h post-marathon
in the placebo group [43]. Unlike the tart cherry group,
the placebo group failed to maintain TAS or redox bal-
ance following the endurance exercise, demonstrating
possible antioxidant effectiveness on excessive ROS pro-
duction with bouts of endurance exercise [43]. Childs
et al. [83] analyzing TAS following arm eccentric exercise-
induced injury demonstrated significantly greater TAS
levels with vitamin C +NAC supplementation compared
to placebo 48-h through 7-d post-exercise in healthy,
untrained males. A resistance training-related study con-
ducted by Lafay et al. [84] investigating the effects of a
polyphenol-rich grape extract on repeated jumping force
capacity, found a significant jumping force capacity
improvement in the grape extract group over placebo.
However, similar to the current study, Lafay et al. [84]
found no significant difference in SOD activity between
the groups. The current resistance training study also did
not demonstrate any significant change in TAS activity
across time or between groups possibly attributed to dif-
ferences in study population and the low metabolic cost
associated with resistance/eccentric exercise versus endur-
ance exercise.
The strengths of this particular study revolve around the
analysis of a large cohort of muscle soreness, performance,
muscle damage, inflammatory, and oxidative damage mea-
sures to contribute a comprehensive analysis to the existing
body of published literature. This type of comprehensive
hemodynamic analysis has not been conducted in a tart
cherry supplement study paired with resistance exercise.
Further, the current study employed one of the largest sub-
ject cohorts among recent studies examining polyphenolic,
vitamin, or NSAID supplementation effects on perform-
ance and related hemodynamic markers. The utilization of
this supplement within the free-living resistance trained
population demonstrated its effectiveness under normative
training, diet, and performance conditions. The ease asso-
ciated with consuming an encapsulated powdered supple-
ment versus a potentially inconvenient or unpalatable juice
most likely enhanced subject compliance with supplemen-
tation. Potential limitations and weakness of the current
study should also be considered. The placebo-control
matched design of this study was effective in equalizing
study subject exposure to the resistance protocol irre-
spective of supplement group, however compared to a
cross-over design, there might have been some variabil-
ity associated with subject pairing. Differences in resist-
ance training experience and overall state of training
beyond the study inclusion/exclusion criteria may also
have been a source of variability in study cohort recruit-
ment. Due to the large number of hemodynamic markers
measured in this study, the five selected time points of
blood draws over the course of the experimental period
may have not captured the entire pharmacokinetic profile
for each marker. Despite controlling 48-h training activity
and NSAID intake with a 10-h fast before each session,
nutritional intake and hydration status of each subject was
not controlled nor tested. Differences in nutrition and hy-
dration among study subjects could have been a potential
source of hemodynamic marker or performance measure
variability in a cohort of this size. Further, the 48-hour
NSAID ingestion limitation may not have been a sufficient
washout time for all NSAID-type medications considering
the large range in reported half-life of common NSAIDs
(1.6 to 30-h). The major overriding strengths of this study
are that this is the first practical study to be conducted
surrounding an acute bout of strength exercise incorporat-
ing significant muscle mass recruitment and it is the first
study to be conducted utilizing a powdered form of cher-
ries rather than a juice or concentrate.
Conclusions
The current study demonstrated that consumption of a
Montmorency powdered tart cherry supplement 7-d
before, the day of, and 2-d after completing a single bout
of high volume, high-intensity resistance exercise, ap-
pears to be an effective dietary supplement in reducing
muscle soreness across the most biomechanically loaded
region of the quadriceps near the distal patellar attach-
ment and markers of muscle catabolism in resistance
trained individuals. Short-term supplementation with pow-
dered tart cherry surrounding a single bout of resistance
training did not demonstrate any definitive effect on
markers of oxidative damage or inflammation. Due to the
inconclusive oxidative damage and inflammatory evidence,
mechanisms of short-term powdered tart cherry and other
related phytochemical-containing nutritional supplements
surrounding bouts of high intensity, anaerobic and resist-
ance exercise need to be further investigated. Additional
examination of powdered tart cherry supplementation with
other forms of exercise that are known to promote a more
pronounced effect on inflammation and oxidative stress
(e.g. endurance exercise) is also needed. However, the initial
effectiveness in reducing perceptions of muscle soreness
and markers of muscle catabolism in resistance-trained
men demonstrates that powdered tart cherry supplementa-
tion provides similar benefits as previously studied tart
cherry juices or concentrates following acute bouts of lower
body strength-based exercise.
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